CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 44 enrolled
Drug / intervention
Pioglitazone +1 moredrug
Likely dose
Pioglitazone 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00639457
NCT00639457N/ACompleted
CompareCT.gov

Exercise and Pioglitazone for HIV-Metabolic Syndromes

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·interventional·Posted Mar 20, 2008·Updated Oct 23, 2013

In Brief

A clinical study evaluating Pioglitazone and Exercise training for HIV Infections and 6 related conditions. Completed, enrolled 44 participants across 1 site.

Detailed Summary

The purpose is to examine the safety and efficacy of 16wks of pioglitazone (Actos; 30mg/d) with and without aerobic and strength exercise training for reducing glucose intolerance and central adiposity in HIV-infected people. We anticipate that pioglitazone + exercise training will improve glucose metabolism and insulin sensitivity, and reduce central adiposity more than pioglitazone alone. These improvements should translate into reduced cardiovascular disease risk in HIV-infected people.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 20, 2008
Enrollment StartJan 1, 2005
Primary CompletionDec 1, 2008
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.3 years ago

Interventions

Pioglitazonedrug

Oral 30mg/day for 16 weeks

Exercise trainingbehavioral

Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks